Janux Therapeutics, Inc.
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
JANX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US47103J1051
- LEI:
- Country:
- United States of America
- Address:
- 10955 VISTA SORRENTO PARKWAY, 92130 SAN DIEGO
- Website:
- https://www.januxrx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for the treatment of cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) technology platforms to create novel therapeutics. These platforms are designed to generate bispecific and other immunomodulating molecules that are conditionally activated within the tumor microenvironment. This targeted approach aims to stimulate a tumor-specific immune response to kill cancer cells while minimizing the systemic toxicities associated with conventional immunotherapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Janux Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Janux Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Janux Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
